A Single Dose Could Reshape Immunity Against the Deadliest Viruses
A team of researchers from the Massachusetts Institute of Technology (MIT) and the Scripps Research Institute has developed a groundbreaking method to enhance the immune response against HIV using just a single vaccine dose, by combining two powerful immune-boosting agents.
In experiments conducted on mice, results showed that the combination of traditional 'alum' and a new immune adjuvant called SMNP led to the production of more diverse and larger quantities of antibodies, compared to using the vaccine alone or with just one adjuvant. This development not only opens promising avenues for HIV prevention, but could also accelerate the creation of effective single-dose vaccines for other infectious diseases such as COVID-19 and influenza.
The researchers based their study on a modified HIV protein known as MD39, used as an antigen attached to alum particles with the addition of SMNP. Following vaccination, the team observed that this combination remained stable in lymph nodes for up to a month, giving the immune system more time to build a strong and targeted response.
Professor J. Christopher Love, one of the lead researchers, explained:
'This method mimics what happens during natural infection, where the antigen remains in the body for a long time, giving immune cells the opportunity to strengthen their defenses.'
By analyzing B cells in the mice, researchers found that the enhanced vaccine produced a broader and greater quantity of antibodies, increasing the likelihood of generating 'broadly neutralizing' antibodies capable of targeting multiple strains of HIV.
Love added:
'The more opportunities we give the immune system to explore different options, the higher the chances of producing effective antibodies against a wider range of viruses.'
The study, published in Science Translational Medicine, suggests that the approach can be applied to protein-based vaccines for various diseases. Additionally, the components used are already familiar to health authorities, which could speed up regulatory approval.
Love concluded:
'The true strength of this approach lies in its simplicity and effectiveness. It doesn't require new technologies, just a smarter use of existing tools to develop stronger, faster vaccines.'
The research was supported by the U.S. National Institutes of Health (NIH), the Koch Institute, the Ragon Institute, and the Howard Hughes Medical Institute.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Morocco World
16 hours ago
- Morocco World
Moroccan Biologist Jinane Zouaki Joins Ibero-American Academy of Pharmacy
Rabat – Moroccan biologist Jinane Zouaki has been appointed as an academic corresponding member of the Ibero-American Academy of Pharmacy. Her appointment marks a big milestone, as she is the first Moroccan, Arab, and African woman to receive this honor. The official ceremony took place on Tuesday at the Faculty of Pharmacy in Granada, Spain. The event gathered many scientists from Spain, Portugal, Latin America, and Morocco. In her speech to the academy, Zouaki spoke about her history of pharmacy in Morocco. She outlined the country's recent efforts to strengthen its health sovereignty under the leadership of King Mohammed VI. She explained that this national strategy has helped Morocco become a leading industrial hub and a strong, competitive player in both regional and international healthcare sectors. Speaking to Morocco's state news agency MAP, Zouaki shared her pride and gratitude for joining such a prestigious institution. She said the recognition is not only a personal achievement, but also a proud moment for Moroccan women and for the country as a whole. This recognition contributes to Morocco's scientific presence on the international stage, she added. Originally from the northern city of Tetouan, Zouaki holds a doctorate in pharmacy. In 2022, she became the first Moroccan and African to receive the Medal of Privilege from the University of Granada, a high honor that celebrates her long journey in education and biomedical research. Zouaki also made history as the first Moroccan to join the Royal Academy of Pharmacy of Catalonia. During the COVID-19 pandemic, she volunteered to help medical teams. At her molecular biology lab in Saniat Rmel Hospital in Tetouan, she worked on COVID-19 testing and helped train healthcare workers. Tags: HealthMoroccopharmacy
Alalam24
7 days ago
- Alalam24
A Single Dose Could Reshape Immunity Against the Deadliest Viruses
A team of researchers from the Massachusetts Institute of Technology (MIT) and the Scripps Research Institute has developed a groundbreaking method to enhance the immune response against HIV using just a single vaccine dose, by combining two powerful immune-boosting agents. In experiments conducted on mice, results showed that the combination of traditional 'alum' and a new immune adjuvant called SMNP led to the production of more diverse and larger quantities of antibodies, compared to using the vaccine alone or with just one adjuvant. This development not only opens promising avenues for HIV prevention, but could also accelerate the creation of effective single-dose vaccines for other infectious diseases such as COVID-19 and influenza. The researchers based their study on a modified HIV protein known as MD39, used as an antigen attached to alum particles with the addition of SMNP. Following vaccination, the team observed that this combination remained stable in lymph nodes for up to a month, giving the immune system more time to build a strong and targeted response. Professor J. Christopher Love, one of the lead researchers, explained: 'This method mimics what happens during natural infection, where the antigen remains in the body for a long time, giving immune cells the opportunity to strengthen their defenses.' By analyzing B cells in the mice, researchers found that the enhanced vaccine produced a broader and greater quantity of antibodies, increasing the likelihood of generating 'broadly neutralizing' antibodies capable of targeting multiple strains of HIV. Love added: 'The more opportunities we give the immune system to explore different options, the higher the chances of producing effective antibodies against a wider range of viruses.' The study, published in Science Translational Medicine, suggests that the approach can be applied to protein-based vaccines for various diseases. Additionally, the components used are already familiar to health authorities, which could speed up regulatory approval. Love concluded: 'The true strength of this approach lies in its simplicity and effectiveness. It doesn't require new technologies, just a smarter use of existing tools to develop stronger, faster vaccines.' The research was supported by the U.S. National Institutes of Health (NIH), the Koch Institute, the Ragon Institute, and the Howard Hughes Medical Institute.
Morocco World
09-06-2025
- Morocco World
New Covid-19 Variant Rapidly Spreads Across Continents
Rabat — A newly identified COVID-19 variant known as NB.1.8.1 is spreading rapidly across multiple parts of the world, raising concerns among global health experts. The variant, which belongs to the Omicron family, was first detected in January 2025 and has since reached countries including the United States, United Kingdom, Australia, China, India, Maldives and Egypt. According to British news reports, doctors in Ireland have reported that NB.1.8.1 is causing unusual symptoms compared to previous strains. In addition to common signs like sore throat and fatigue, patients are also experiencing gastrointestinal problems such as nausea, diarrhea, vomiting, heartburn, bloating, and abdominal pain. Irish health authorities are urging anyone with these symptoms to stay home and avoid contact with others until 48 hours after symptoms resolve, warning that the illness could be mistaken for seasonal colds or stomach bugs. The World Health Organization (WHO) has officially labeled it a 'Variant Under Monitoring,' meaning it is spreading fast enough to warrant attention, but not enough to be classified as a major threat. The Global Virus Network, a leading coalition of virologists and medical researchers, says there is no current evidence that this variant causes more severe illness than previous ones. Like earlier Omicron sub-variants, NB.1.8.1 includes genetic changes that help it spread more easily, but vaccines—especially updated booster doses—continue to protect from the most severe effects. While breakthrough infections can still happen, especially among people who are unvaccinated or have not received a recent booster, vaccinated individuals are reportedly far less likely to suffer serious illness. Health experts stress that the main benefit of COVID-19 vaccination is not avoiding infection altogether, but avoiding severe outcomes like hospitalization, long-term complications, or death. Global spread Recent data from the WHO shows that NB.18.1 has been detected in at least 22 countries. Between late April and early May, the variant grew from just 2.5 percent to over 10 percent of global samples. In India, over 4,300 active COVID-19 cases have been reported as of early June, with nearly 300 new infections in a single day. Several states, including Delhi and Kerala, have seen consistent rises in cases. In Taiwan, hospital visits linked to COVID-19 symptoms rose nearly 80 percent in one week at the end of April. In the US, the variant has been identified in multiple states, first through airport screening and later in community cases, including in Washington, Ohio, and Hawaii. The US continues to report roughly 300 COVID-related deaths each week. In response to this growing spread, the Global Virus Network is urging eligible individuals to get vaccinated or boosted. Adults over 65, people with chronic health conditions, and pregnant individuals are strongly encouraged to stay up to date on their COVID-19 shots. Pediatric vaccination is also being emphasized, particularly for children who have not received an updated dose in the past year. Vaccination during pregnancy, experts note, offers significant protection to both mother and baby, lowering the risk of hospitalization for infants and reducing complications related to COVID-19 infection during pregnancy. Although the rise of NB.1.8.1 has not triggered emergency action, experts say it is a clear reminder of the need for strong global surveillance, continued scientific cooperation, and public awareness. The emergence of new variants is expected, they stress, and should be met with preparation rather than panic. This moment, they say, is not a crisis—but a chance to stay ahead.
